The company has successfully developed a number of innovative products (MitoXpress®-Xtra, MitoXpress®-Intra, pH-Xtra and MitoImageTM probe families, Optech® and GreenLight® sensor systems), grown to 13 employees and developed a thriving international market including plate reader screens for drug safety, mitochondrial toxicity, cell bioenergetics, microbial growth. These applications have been widely adopted by the pharmaceutical and biotech sectors, and numerous academic research labs across life and biomedical sciences.
The outstanding innovations and commercial developments of Luxcel have attracted the attention of global leader Agilent who have purchased the company, highlighting the value of the research activity, potential for commercial growth and strategic fit in Agilent’s Live Cell Analysis Division and technology portfolio. This partnership will open new opportunities for the company and indeed continued collaboration with Dmitri’s research team is envisaged.
This new relationship promises to accelerate new product introductions by leveraging Agilent’s R&D and global commercial infrastructures with our unique biosensor chemistries and assay development expertise.
The initial patents on this technology were filed by UCC in 2002 with subsidiary applications in 2005, 2008 and 2011 creating a portfolio of technologies that were licensed to the company. This technology arose from research funded from national and European sources, particularly Enterprise Ireland.